Chemical Reprogramming Cocktails
Chemical reprogramming cocktails (small-molecule induced pluripotency and partial reprogramming)
Written by Aaron CuhaReviewed Sep 2026
Also known as: CiPSC, Chemically induced pluripotent stem cells, Small-molecule reprogramming, Chemical age reversal cocktails
Combinations of small molecules that replace the gene therapy in reprogramming. All of the ageing work is in cells in a dish, plus one lifespan result in a nematode.
Overview
Every reprogramming approach with an ageing result behind it delivers transcription factors with a virus. Chemical reprogramming is the attempt to do the same thing with small molecules, which would remove the viral vector, the genetic cassette and the manufacturing problem in one step. In 2022, a Nature paper reported the first chemical reprogramming of human somatic cells to pluripotent stem cells, achieved by first inducing an intermediate plastic state; a 2023 Cell Stem Cell paper made the process faster and more efficient.
Applied to ageing rather than to pluripotency, the work is at an earlier stage again. A 2023 paper in Aging screened for molecules that reverse cellular ageing using transcription-based ageing clocks and a nucleocytoplasmic compartmentalisation assay, and identified six chemical cocktails that restored a youthful genome-wide transcript profile in human cells in under a week without compromising cell identity. A 2025 EMBO Molecular Medicine paper found that chemical partial reprogramming improved genomic instability and epigenetic alterations in aged human cells, identified a two-molecule combination that also reduced senescence and oxidative stress, and reported that this combination extended lifespan and healthspan in Caenorhabditis elegans.
That is the whole record. No human has taken a reprogramming cocktail. No mammal has been given one for an ageing indication in a published study. The lifespan result is in a nematode, which is a screening organism, not a model of mammalian ageing. There is no registered human trial.
Mechanism of action
In vitro, in human cells. Small-molecule combinations induce an intermediate plastic state that permits reprogramming without transcription-factor delivery; inhibition of the JNK pathway was identified as necessary to induce that plasticity by suppressing pro-inflammatory pathways. For the ageing application, the readouts are transcriptomic age, nucleocytoplasmic compartmentalisation, genomic instability, senescence markers and oxidative stress, all measured in cultured human cells. No mechanism has been established in a living mammal, and none in a person.
Human evidence
None. No human has received a chemical reprogramming cocktail for any indication. The human element of this literature is that the cells in the dish are human cells, which is not the same thing as human evidence.
What this does not tell you: Cultured cells have no immune system, no liver, no distribution problem and no cancer risk that anyone would notice. A cocktail that resets a transcriptomic clock in a fibroblast has not been shown to be absorbable, tolerable or safe in an animal, let alone a person, and the one whole-organism lifespan result is in a nematode. Nothing here supports taking any small molecule for reprogramming.
Reading the research record
Chemical reprogramming is interesting for a practical reason rather than a biological one. The gene therapy route requires an AAV, a doxycycline-inducible cassette, a manufacturing process and a regulatory pathway for a genetic medicine, which is why the one product in a human trial is injected into a single eye. A pill would sidestep all of that. It would also sidestep the ability to switch the intervention off, which is the safety feature the gene therapy programmes rely on, so the trade is not purely in one direction.
The honest position is that this field is roughly a decade behind the transcription-factor work and the transcription-factor work has no human efficacy data either. Where the OSK literature has mouse organs and one recruiting phase 1, the chemical literature has human cells in dishes and a worm.
The evidence, charted
Fig. 1 · evidence composition
0of 4 citations (0%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2022 to 2025, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- In vitro2022
Chemical reprogramming of human somatic cells to pluripotent stem cells
Human cells in culture. The first chemical reprogramming of human somatic cells to pluripotent stem cells, achieved by creating an intermediate plastic state. The JNK pathway was identified as a major barrier, and its inhibition was indispensable for inducing plasticity and a regeneration-like programme by suppressing pro-inflammatory pathways.
Nature - In vitro2023
Highly efficient and rapid generation of human pluripotent stem cells by chemical reprogramming
Human cells in culture. An improved chemical protocol generating human pluripotent stem cells faster and at higher efficiency than the 2022 method.
Cell Stem Cell - In vitro2023
Chemically induced reprogramming to reverse cellular aging
Human cells in culture. High-throughput assays distinguishing young from old and senescent cells, including transcription-based ageing clocks and a real-time nucleocytoplasmic compartmentalisation assay, identified six chemical cocktails that restored a youthful genome-wide transcript profile and reversed transcriptomic age in under a week without compromising cellular identity. NIH funded with non-US government support.
Aging (Albany NY) - Animal2025
Chemical reprogramming ameliorates cellular hallmarks of aging and extends lifespan
Aged human cells in culture plus Caenorhabditis elegans. Chemical-induced partial reprogramming improved genomic instability and epigenetic alterations in aged human cells. An optimised two-molecule combination also reduced cellular senescence and oxidative stress, and extended lifespan and healthspan in C. elegans. The lifespan result is in a nematode, not a mammal.
EMBO Molecular Medicine
Frequently asked questions
Can you buy a reprogramming cocktail?
The individual small molecules used in these screens are laboratory reagents and some are sold as such. No cocktail has been tested in a mammal for an ageing indication, none is registered in a human trial, and nothing published supports taking any of them.
Did chemical reprogramming extend lifespan?
In Caenorhabditis elegans, a nematode worm, yes: a 2025 EMBO Molecular Medicine paper reported extended lifespan and healthspan from a two-molecule combination. Worms are a screening organism. No mouse, rat or human lifespan data exist for chemical reprogramming.
How is this different from OSK gene therapy?
OSK delivers transcription factors using a virus and a genetic switch, and has mouse organ-level results plus one recruiting phase 1 trial in the eye. Chemical reprogramming substitutes small molecules for the virus, which would make delivery far simpler, but its ageing results are in cultured human cells and a worm.